Related Experiment Videos
Evaluating glutamatergic transmission in schizophrenia
Carol A Tamminga1, Adrienne C Lahti, Deborah R Medoff
1University of Texas Southwestern Medical School, Dallas, Texas, 75390, USA. ctamming@mprc.umaryland.edu
Annals of the New York Academy of Sciences
|December 20, 2003
Summary
This study synthesizes findings on schizophrenia, the glutamate system, and patient responses to ketamine. It integrates human clinical and brain imaging data with prior animal studies on PCP and MK-801.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is linked to the glutamate system.
- Ketamine shows clinical and brain imaging effects in patients.
- Previous animal studies examined PCP and MK-801's effects.
Purpose of the Study:
- To synthesize existing research on schizophrenia, glutamate, and ketamine.
- To correlate clinical and functional brain imaging responses to ketamine in patients.
- To integrate findings from animal models with human data.
Main Methods:
- Characterization of clinical response in schizophrenia patients to ketamine.
- Functional brain imaging (regional cerebral blood flow - rCBF) response to ketamine.
- Review and synthesis of prior animal studies on PCP and MK-801.
Main Results:
- Ketamine's clinical and rCBF effects in schizophrenia patients were characterized.
- Animal studies provided insights into PCP and MK-801 pharmacology and regional activation.
- This paper synthesizes these disparate findings into a cohesive overview.
Conclusions:
- The glutamate system is a key target for understanding schizophrenia.
- Ketamine's effects in schizophrenia patients are multifaceted, involving clinical and neuroimaging changes.
- Integrating animal and human data offers a comprehensive view of glutamate modulation in schizophrenia.